FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
HOPKINTON, Mass., Oct. 13, 2016 -- Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals will present at the Dawson James Securities 2016 Stock Growth Conference on Thursday, October 20th at 10:45 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida. For more information on the conference or for investors to register, please go to DJS Conference. To view the live audio webcast of the presentation please go to http://ir.springbankpharm.com or http://wsw.com/webcast/dawson2/sbph.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. For more information please visit: www.springbankpharm.com.
About Dawson James Securities
Dawson James Securities, Inc., a member of FINRA/SIPC, is a full service investment bank headquartered in Boca Raton, FL. http://www.dawsonjames.com.
Contact: Jon Freve Chief Financial Officer (508) 500-4956 [email protected]
